Frontlight ResearchEarly access
Neuromyelitis optica (NMOSD) trials in Argentina
2 of 3 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Where
- Ciudad Autonoma Buenos Aires, Córdoba
- Age
- 2 years to 11 years
- People
- 8 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05199688 · EU 2023-507817-85-00 - Phase 2Taking peopleStudy of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
- Where
- Parque Patricios
- Age
- 2 years to 17 years
- People
- 15 worldwide
- Run by
- Amgen
See details and how to joinNCT05549258 · EU 2023-510007-22-00